6:32 PM
 | 
Oct 05, 2009
 |  BC Extra  |  Financial News

SciClone discontinues pancreatic cancer trial

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) fell $0.42 (10%) to $3.73 on Monday after discontinuing a Phase II trial of RP101 (BvdU) to treat advanced...

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >